🇺🇸 FDA
Pipeline program

EPI-589

EPI589-15-001

Phase 2 small_molecule completed

Quick answer

EPI-589 for Amyotrophic Lateral Sclerosis is a Phase 2 program (small_molecule) at PTC THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
PTC THERAPEUTICS, INC.
Indication
Amyotrophic Lateral Sclerosis
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials